NASDAQ:VBIV VBI Vaccines Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding VBI Vaccines Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.91 -0.10 (-3.32 %) (As of 09/24/2020 12:00 AM ET) Add Compare Share Today's Range$2.81Now: $2.91▼$3.0750-Day Range$3.10MA: $3.68▼$4.5152-Week Range$0.47Now: $2.91▼$6.93Volume6.77 million shsAverage Volume10.47 million shsMarket Capitalization$672.79 millionP/E RatioN/ADividend YieldN/ABeta1.79 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus. It is also developing cytomegalovirus vaccine candidate for infectious disease; and glioblastoma multiforme vaccine candidate for immuno-oncology. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. The company is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.6 Analyst's Opinion Consensus RatingVBI Vaccines has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $6.25, VBI Vaccines has a forecasted upside of 114.8% from its current price of $2.91.Amount of Analyst CoverageVBI Vaccines has only been the subject of 3 research reports in the past 90 days. Previous Next 3.3 Community Rank Outperform VotesVBI Vaccines has received 486 “outperform” votes. (Add your “outperform” vote.)Underperform VotesVBI Vaccines has received 258 “underperform” votes. (Add your “underperform” vote.)Community SentimentVBI Vaccines has received 65.32% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about VBI Vaccines and other stocks. Vote “Outperform” if you believe VBIV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe VBIV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldVBI Vaccines does not currently pay a dividend.Dividend GrowthVBI Vaccines does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, VBI Vaccines insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of VBI Vaccines is held by insiders.Percentage Held by Institutions42.59% of the stock of VBI Vaccines is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for VBI Vaccines are expected to decrease in the coming year, from ($0.20) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of VBI Vaccines is -11.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of VBI Vaccines is -11.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVBI Vaccines has a P/B Ratio of 5.82. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.6Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.59 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:VBIV Previous Symbol CUSIPN/A CIK764195 Webwww.vbivaccines.com Phone617-830-3031Debt Debt-to-Equity Ratio0.13 Current Ratio5.86 Quick Ratio5.77Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$2.22 million Price / Sales303.06 Cash FlowN/A Price / Cash FlowN/A Book Value$0.50 per share Price / Book5.82Profitability EPS (Most Recent Fiscal Year)($0.46) Net Income$-54,810,000.00 Net Margins-2,467.47% Return on Equity-46.47% Return on Assets-34.38%Miscellaneous Employees108 Outstanding Shares231,198,000Market Cap$672.79 million Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $2.91 -0.10 (-3.32 %) (As of 09/24/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive VBIV News and Ratings via Email Sign-up to receive the latest news and ratings for VBIV and its competitors with MarketBeat's FREE daily newsletter. VBI Vaccines (NASDAQ:VBIV) Frequently Asked Questions How has VBI Vaccines' stock price been impacted by Coronavirus (COVID-19)? VBI Vaccines' stock was trading at $0.9171 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VBIV stock has increased by 217.3% and is now trading at $2.91. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of VBI Vaccines? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for VBI Vaccines in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for VBI Vaccines. When is VBI Vaccines' next earnings date? VBI Vaccines is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for VBI Vaccines. How were VBI Vaccines' earnings last quarter? VBI Vaccines Inc (NASDAQ:VBIV) released its quarterly earnings results on Friday, July, 31st. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.04). The biopharmaceutical company had revenue of $0.18 million for the quarter, compared to analyst estimates of $0.86 million. VBI Vaccines had a negative net margin of 2,467.47% and a negative return on equity of 46.47%. View VBI Vaccines' earnings history. What price target have analysts set for VBIV? 4 equities research analysts have issued 1-year price objectives for VBI Vaccines' stock. Their forecasts range from $4.00 to $9.00. On average, they anticipate VBI Vaccines' share price to reach $6.25 in the next twelve months. This suggests a possible upside of 114.8% from the stock's current price. View analysts' price targets for VBI Vaccines. Who are some of VBI Vaccines' key competitors? Some companies that are related to VBI Vaccines include Alkermes (ALKS), Pacira Biosciences (PCRX), Agios Pharmaceuticals (AGIO), Aimmune Therapeutics (AIMT), I-Mab (IMAB), IGM Biosciences (IGMS), Apellis Pharmaceuticals (APLS), Xencor (XNCR), Taro Pharmaceutical Industries (TARO), Harmony Biosciences (HRMY), Opko Health (OPK), Karuna Therapeutics (KRTX), Zymeworks (ZYME), Corcept Therapeutics (CORT) and Seres Therapeutics (MCRB). View all competitors. What other stocks do shareholders of VBI Vaccines own? Based on aggregate information from My MarketBeat watchlists, some companies that other VBI Vaccines investors own include Canaccord Genuity (), BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird () and Wellington Shields (). Who are VBI Vaccines' key executives? VBI Vaccines' management team includes the following people: Mr. Jeff R. Baxter, CEO, Pres & Director (Age 58)Dr. David Evander Anderson, Chief Scientific Officer (Age 49)Dr. Francisco Diaz-Mitoma, Chief Medical Officer (Age 64)Mr. Christopher McNulty, CFO & Head of Bus. Devel. (Age 42)Ms. Athena Kartsaklis, Sr. VP of Fin., Chief Compliance Officer & Principal Financial Officer (Age 54) What is VBI Vaccines' stock symbol? VBI Vaccines trades on the NASDAQ under the ticker symbol "VBIV." Who are VBI Vaccines' major shareholders? VBI Vaccines' stock is owned by many different retail and institutional investors. Top institutional shareholders include Perceptive Advisors LLC (23.81%), Cambridge Investment Research Advisors Inc. (0.74%), General American Investors Co. Inc. (0.50%), Nuveen Asset Management LLC (0.35%), Bank of New York Mellon Corp (0.28%) and Canada Pension Plan Investment Board (0.26%). Company insiders that own VBI Vaccines stock include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis and Tomer Kariv. View institutional ownership trends for VBI Vaccines. Which institutional investors are selling VBI Vaccines stock? VBIV stock was sold by a variety of institutional investors in the last quarter, including Premier Asset Management LLC, General American Investors Co. Inc., Goldman Sachs Group Inc., Raymond James Financial Services Advisors Inc., and UBS Group AG. View insider buying and selling activity for VBI Vaccines. Which institutional investors are buying VBI Vaccines stock? VBIV stock was acquired by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Canada Pension Plan Investment Board, California Public Employees Retirement System, Dupont Capital Management Corp, State of Wisconsin Investment Board, Two Sigma Advisers LP, Alyeska Investment Group L.P., and Federated Hermes Inc.. Company insiders that have bought VBI Vaccines stock in the last two years include Christopher Mcnulty, Francisco Diaz-Mitoma, Jeff Baxter, Life Sciences Maste Perceptive, Nell Beattie, Perceptive Advisors Llc, Steven Gillis, and Tomer Kariv. View insider buying and selling activity for VBI Vaccines. How do I buy shares of VBI Vaccines? Shares of VBIV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is VBI Vaccines' stock price today? One share of VBIV stock can currently be purchased for approximately $2.91. How big of a company is VBI Vaccines? VBI Vaccines has a market capitalization of $672.79 million and generates $2.22 million in revenue each year. The biopharmaceutical company earns $-54,810,000.00 in net income (profit) each year or ($0.46) on an earnings per share basis. VBI Vaccines employs 108 workers across the globe. What is VBI Vaccines' official website? The official website for VBI Vaccines is www.vbivaccines.com. How can I contact VBI Vaccines? VBI Vaccines' mailing address is 222 Third Street Suite 2241, Cambridge MA, 02142. The biopharmaceutical company can be reached via phone at 617-830-3031 or via email at [email protected] This page was last updated on 9/24/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
